Glenmark Pharmaceuticals Ltd

- Glenmark aims to maintain a **zero gross debt balance sheet going forward**, indicating no plans for future debt fundraising. - For IGI (a Glenmark subsidiary), the company has **allocated $70 million per annum for the next 3 years** as capital, which will be self-funded through internal resources. - Beyond 3 years, IGI might explore additional funding via: - Milestones from partnered assets, - Potential new deals for existing programs, - **Possibly an IPO to raise additional funds**. - Overall, Glenmark is focusing on **prudent capital allocation and generating strong free cash flow** to fund business growth. - No explicit mention of raising debt or equity at the consolidated Glenmark level in the near term; emphasis is on self-funding and cash generation.

- Glenmark has allocated capital to its subsidiary IGI for capex at about $70 million per annum for the next 3 years, totaling approximately $210-225 million. - Most of this capex allocation has been managed through intercompany flows and treasury management within Glenmark entities. - The company expects continued investment in innovation, including multi-specific antibody platforms and next-generation programs, with assets entering clinical trials over the next 5 years. - Capex spent in H1 FY'26 was around INR 500 crores. - Glenmark emphasizes prudent capital allocation going forward focused on organic growth and innovation. - The company is targeting strong free cash flow generation while maintaining zero gross debt. - There is a focus on building inventories to support growth, considered a normal operational investment.

- Glenmark aims for approximately 15% annual sales growth going forward. (Page 11) - India business showed 17% growth recently and is expected to return to an INR1,150-1,200 crore run rate from Q3 FY '26. (Pages 6, 13) - India business revenue is projected to exceed INR4,800 crores in FY '27. (Page 6) - U.S. business continues strong growth with upcoming respiratory launches and next 3 Sole FTF/exclusive products. (Page 6) - Multi-specific platform assets expected to start entering clinical trials over next 5 years, supporting innovation pipeline growth. (Page 19) - Glenmark 3.0 phase expected to be a "glorious phase" over next 5-10 years with transformational growth and transition to a branded-led company globally. (Pages 6, 17)

- Glenmark aims for a sales growth of around 15% annually going forward (Page 11 and 19). - EBITDA margin target is approximately 23% immediately, improving to around 25% in the future (Page 11 and 19). - The company expects strong free cash flow generation starting FY '27 and beyond (Page 11 and 19). - ROCE is projected to improve from 25% to 30%, with a focus on further enhancement as the portfolio becomes more innovation-driven (Page 19). - Glenmark 3.0 phase is expected to bring a robust margin trajectory and strong balance sheet with zero gross debt (Page 8 and 19). - The India business is expected to deliver over INR 4,800 crores in top-line revenues in FY '27, supporting overall growth (Page 6). - The company anticipates consistent growth in branded portfolio and continued innovation-led value creation (Page 19).

The provided pages of Glenmark Pharmaceuticals' Q2 FY '26 Earnings Call transcript do not explicitly mention the current or expected order book or pending orders details. Key focuses in the transcript include: - Strong growth outlook, especially for India business with expected FY '27 revenues over INR 4,800 crores. - Business entering "Glenmark 3.0" phase emphasizing branded-led growth globally. - Restocking anticipated in India market from Q3 after distributor inventory corrections. - U.S. business growth driven by respiratory launches and in-licensed products. - Multi-specific antibody platform assets expected to enter clinics over the next 5 years. - Commitment to prudent capital allocation and strong free cash flow generation. No direct numeric data on order book or pending orders was disclosed on the shared pages. For precise order book figures, one might need to refer to the full report or other sections.